Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.